Efficacy of Osimertinib in Patients With Lung Cancer
Recruiting
- Conditions
- Advanced Non-Small Cell Lung Cancer
- Registration Number
- NCT06174857
- Lead Sponsor
- Hunan Province Tumor Hospital
- Brief Summary
This is a descriptive observational study, in which data are collected in an epidemiological fashion and prospective. This study does not intend to intervene the current medical practice of the recruited patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Patients must be ≥18 years.
- Provision of fully informed consent prior to any study specific procedures.
- Advanced or metastatic lung squamous cell carcinoma confirmed by histology or cytology.
- According to the RECIST 1.1 standard, the patient must have at least one measurable lesion.
Exclusion Criteria
- None
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival 3 years From registration onto that step until death, or censored at the date of last contact.
progression-free survival 3 years From registration onto that step until death, or censored at the date of last contact.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Hunan Cancer hospital
🇨🇳Changsha, Hunan, China